Suchergebnisse - Portal für Medizinische Datenmodelle (MDM-Portal)

Suchergebnisse filtern
Datenmodelle auswählen

Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

380 Suchergebnisse.

FOLLOW UP FORM (S0100)

- 22.01.15 - 1 Formular, 7 Itemgruppen, 24 Datenelemente, 1 Sprache

Itemgruppen: VITAL STATUS, Disease Follow Up Status, NOTICE OF FIRST RELAPSE OR PROGRESSION, NOTICE OF NEW PRIMARY, NON-PROTOCOL TREATMENT, LONG TERM TOXICITY, CCRR MODULE

S0100 FOLLOW UP FORM Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=AEB52E43-75AF-43F2-E034-0003BA12F5E7

Leukemia Follow-Up - S0100 CNS LEUKEMIA EVALUATION FORM - S0100 CNS LEUKEMIA EVALUATION FORM

- 22.01.15 - 1 Formular, 2 Itemgruppen, 8 Datenelemente, 1 Sprache

Itemgruppen: Header, LUMBAR PUNCTURE

S0100 CNS LEUKEMIA EVALUATION FORM Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=AEB474AE-AD1A-426C-E034-0003BA12F5E7

Long-Term Follow-up Form Leukemia (NCT00049517)

- 10.01.15 - 1 Formular, 8 Itemgruppen, 30 Datenelemente, 1 Sprache

Itemgruppen: Header, Vital Status, Disease Follow-up Status, Relapse, New Primary, Toxicity, Non-Protocol Therapy, Transfusions

E1900 Long-Term Follow-up Form Combination Chemotherapy With or Without Monoclonal Antibody Therapy Followed by Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia NCT00049517 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A7294868-3C8F-2FCA-E034-0003BA0B1A09

Toxicity - Acute Leukemia (ALL, AML)/Myelodysplastic Syndrome (MDS) - Adverse Event Form - 2019363v3.0 - Acute Leukemia (ALL, AML)/Myelodysplastic Syndrome (MDS) - Adverse Event Form

- 09.01.15 - 1 Formular, 4 Itemgruppen, 25 Datenelemente, 1 Sprache

Itemgruppen: CRF Header, ALL/AML/MDS: Form Administration, ALL/AML/MDS: Adverse Events, Comments

Acute Leukemia (ALL, AML)/Myelodysplastic Syndrome (MDS) - Adverse Event Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=1A9C4726-156D-4A08-E044-0003BA3F9857

Leukemia NCT00492856 Toxicity - SOUTHWEST ONCOLOGY GROUP Consolidation #3 and #4 Adverse Event Summary Form (S0521) - 2416199v1.0 - SOUTHWEST ONCOLOGY GROUP Consolidation #3 and #4 Adverse Event Summary Form (S0521)

- 09.01.15 - 1 Formular, 3 Itemgruppen, 17 Datenelemente, 1 Sprache

Itemgruppen: Header, Adverse Events, Comments

SOUTHWEST ONCOLOGY GROUP Consolidation #3 and #4 Adverse Event Summary Form (S0521) Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=02DF0EAC-60B5-4B6D-E044-0003BA3F9857

Leukemia NCT00492856 Toxicity - SOUTHWEST ONCOLOGY GROUP Post-Consolidation Adverse Event Summary Form: Maintenance Chemotherapy (S0521) - 2416541v1.0 - SOUTHWEST ONCOLOGY GROUP Post-Consolidation Adverse Event Summary Form: Maintenance Chemotherapy (S0521)

- 09.01.15 - 1 Formular, 3 Itemgruppen, 17 Datenelemente, 1 Sprache

Itemgruppen: Header, Adverse Events, Comments

SOUTHWEST ONCOLOGY GROUP Post-Consolidation Adverse Event Summary Form: Maintenance Chemotherapy (S0521) Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=02DFCC65-BC50-09BA-E044-0003BA3F9857

Leukemia NCT00492856 Toxicity - SOUTHWEST ONCOLOGY GROUP Induction Adverse Event Summary Form (S0521) - 2415259v1.0 - SOUTHWEST ONCOLOGY GROUP Induction Adverse Event Summary Form (S0521)

- 09.01.15 - 1 Formular, 3 Itemgruppen, 17 Datenelemente, 1 Sprache

Itemgruppen: Header, Adverse Events, Comments

SOUTHWEST ONCOLOGY GROUP Induction Adverse Event Summary Form (S0521) Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=02C81B59-5981-2968-E044-0003BA3F9857

Leukemia NCT00492856 Toxicity - SOUTHWEST ONCOLOGY GROUP Post-Consolidation Adverse Event Summary Form: Gemtuzumab Ozogamicin (S0521) - 2466569v1.0 - SOUTHWEST ONCOLOGY GROUP Post-Consolidation Adverse Event Summary Form: Gemtuzumab Ozogamicin (S0521)

- 09.01.15 - 1 Formular, 3 Itemgruppen, 17 Datenelemente, 1 Sprache

Itemgruppen: Header, Adverse Events, Comments

SOUTHWEST ONCOLOGY GROUP Post-Consolidation Adverse Event Summary Form: Gemtuzumab Ozogamicin (S0521) Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=10260116-E797-475F-E044-0003BA3F9857

Leukemia NCT00492856 Toxicity - SOUTHWEST ONCOLOGY GROUP Consolidation #1 and #2 Adverse Event Summary Form (S0521) - 2415914v1.0 - SOUTHWEST ONCOLOGY GROUP Consolidation #1 and #2 Adverse Event Summary Form (S0521)

- 09.01.15 - 1 Formular, 3 Itemgruppen, 18 Datenelemente, 1 Sprache

Itemgruppen: Header, Adverse Events, Comments

SOUTHWEST ONCOLOGY GROUP Consolidation #1 and #2 Adverse Event Summary Form (S0521) Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=02DAA575-2A50-6603-E044-0003BA3F9857

Leukemia NCT00049517 Lab - E1900 Cover Page for Hematology Form - 2075140v3.0 - E1900 Cover Page for Hematology Form

- 09.01.15 - 1 Formular, 4 Itemgruppen, 12 Datenelemente, 1 Sprache

Itemgruppen: Header, On Treatment, Off Treatment, CCRR MODULE

E1900 Cover Page for Hematology Form Combination Chemotherapy With or Without Monoclonal Antibody Therapy Followed by Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B19AB29D-AC61-25E1-E034-0003BA12F5E7

Leukemia NCT00049517 Toxicity - E1900 Cover Page for Adverse Event Form - 2075062v3.0 - E1900 Cover Page for Adverse Event Form

- 09.01.15 - 1 Formular, 4 Itemgruppen, 12 Datenelemente, 1 Sprache

Itemgruppen: Header, On Treatment, Off Treatment, CCRR MODULE

E1900 Cover Page for Adverse Event Form Combination Chemotherapy With or Without Monoclonal Antibody Therapy Followed by Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B19AAD35-91C7-25DB-E034-0003BA12F5E7

Leukemia NCT00085124 Follow-Up - CALGB: 10201 Notification of death - 2076956v3.0 - CALGB: 10201 Notification of death

- 09.01.15 - 1 Formular, 1 Itemgruppe, 16 Datenelemente, 1 Sprache

Itemgruppe: CCRR MODULE

CALGB: 10201 Notification of death Daunorubicin and Cytarabine With or Without Oblimersen in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B22B0174-18C2-5157-E034-0003BA12F5E7

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.